

Ophthalmic Drugs Market (Therapeutic Class: Anti-VEGF Agents, Anti-glaucoma Drugs, Anti-inflammatory Drugs, Anti-infective Drugs, Anti-allergy Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Report | 2023-05-11 | 292 pages | Transparency Market Research

AVAILABLE LICENSES:

- Single User License \$5795.00
- Multi User License \$8795.00
- Global Site License \$11795.00

Report description:

Ophthalmic Drugs Market - Scope of Report

TMR's report on the global Ophthalmic Drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Ophthalmic Drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Ophthalmic Drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Ophthalmic Drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Ophthalmic Drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Ophthalmic Drugs

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Ophthalmic Drugs market.

The report delves into the competitive landscape of the global Ophthalmic Drugs market. Key players operating in the global Ophthalmic Drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Ophthalmic Drugs market profiled in this report.

Key Questions Answered in Global Ophthalmic Drugs Market Report

- What is the sales/revenue generated by Ophthalmic Drugs across all regions during the forecast period?
- What are the opportunities in the global Ophthalmic Drugs market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?

Ophthalmic Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global Ophthalmic Drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Ophthalmic Drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Ophthalmic Drugs market.

Table of Contents:

1. Preface
 - ? ? 1.1. Market Definition and Scope
 - ? ? 1.2. Market Segmentation
 - ? ? 1.3. Key Research Objectives
 - ? ? 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ophthalmic Drugs Market
4. Market Overview
 - ? ? 4.1. Introduction
 - ? ? ? ? 4.1.1. Segment Definition
 - ? ? 4.2. Overview
 - ? ? 4.3. Market Dynamics
 - ? ? ? ? 4.3.1. Drivers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

? ? ? ? 4.3.2. Restraints
? ? ? ? 4.3.3. Opportunities
? ? 4.4. Global Ophthalmic Drugs Market Volume Forecast, by Dosage Form, 2017-2031
5. Key Insights
? ? 5.1. Disease Prevalence & Incidence rate globally with key countries
? ? 5.2. Pipeline Analysis
? ? 5.3. Key Industry Events
? ? 5.4. Covid-19 Pandemic Impact on the Industry
6. Global Ophthalmic Drugs Market Analysis and Forecast, by Therapeutic Class
? ? 6.1. Introduction & Definition
? ? 6.2. Key Findings / Developments
? ? 6.3. Market Value Forecast, by Therapeutic Class, 2017-2031
? ? ? ? 6.3.1. Anti-VEGF Agents
? ? ? ? 6.3.2. Anti-glucoma Drugs
? ? ? ? ? 6.3.2.1. Alpha Agonist
? ? ? ? ? 6.3.2.2. Beta Blockers
? ? ? ? ? 6.3.2.3. Prostaglandin Analogs
? ? ? ? ? 6.3.2.4. Combined Medication
? ? ? ? ? 6.3.2.5. Others
? ? ? ? 6.3.3. Anti-inflammatory Drugs
? ? ? ? ? 6.3.3.1. Steroids
? ? ? ? ? 6.3.3.2. NSAIDs
? ? ? ? 6.3.4. Anti-infective Drugs
? ? ? ? ? 6.3.4.1. Anti-bacterial Drugs
? ? ? ? ? 6.3.4.2. Anti-fungal Drugs
? ? ? ? ? 6.3.4.3. Others
? ? ? ? 6.3.5. Anti-allergy Drugs
? ? ? ? 6.3.6. Others
? ? 6.4. Market Attractiveness Analysis, by Therapeutic Class
7. Global Ophthalmic Drugs Market Analysis and Forecast, by Indication
? ? 7.1. Introduction & Definition
? ? 7.2. Key Findings / Developments
? ? 7.3. Market Value Forecast, by Indication, 2017-2031
? ? ? ? 7.3.1. Dry Eye
? ? ? ? 7.3.2. Glaucoma
? ? ? ? 7.3.3. Infection/Inflammation
? ? ? ? 7.3.4. Retinal Disorders
? ? ? ? ? 7.3.4.1. Wet AMD
? ? ? ? ? 7.3.4.2. Dry AMD
? ? ? ? ? 7.3.4.3. Diabetic Retinopathy
? ? ? ? ? 7.3.4.4. Others
? ? ? ? 7.3.5. Allergy
? ? ? ? 7.3.6. Uveitis
? ? ? ? 7.3.7. Others
? ? 7.4. Market Attractiveness Analysis, by Indication
8. Global Ophthalmic Drugs Market Analysis and Forecast, by Route of Administration
? ? 8.1. Introduction & Definition

? ? 8.2. Key Findings / Developments
? ? 8.3. Market Value Forecast, by Route of Administration, 2017-2031
? ? ? ? 8.3.1. Topical
? ? ? ? 8.3.2. Local Ocular (intravitreal)
? ? ? ? 8.3.3. Others
? ? 8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Ophthalmic Drugs Market Analysis and Forecast, by Product Type
? ? 9.1. Introduction & Definition
? ? 9.2. Key Findings / Developments
? ? 9.3. Market Value Forecast, by Product Type, 2017-2031
? ? ? ? 9.3.1. Prescription
? ? ? ? 9.3.2. OTC
? ? 9.4. Market Attractiveness Analysis, by Product Type
10. Global Ophthalmic Drugs Market Analysis and Forecast, by Dosage Form
? ? 10.1. Introduction & Definition
? ? 10.2. Key Findings / Developments
? ? 10.3. Market Value Forecast, by Dosage Form, 2017-2031
? ? ? ? 10.3.1. Eye Drops
? ? ? ? 10.3.2. Eye Solutions & Suspensions
? ? ? ? 10.3.3. Capsules & Tablets
? ? ? ? 10.3.4. Gels
? ? ? ? 10.3.5. Ointments
? ? ? ? 10.3.6. Others
? ? 10.4. Market Attractiveness Analysis, by Dosage Form
11. Global Ophthalmic Drugs Market Analysis and Forecast, by Distribution Channel
? ? 11.1. Introduction & Definition
? ? 11.2. Key Findings / Developments
? ? 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
? ? ? ? 11.3.1. Hospital Pharmacies
? ? ? ? 11.3.2. Retail Pharmacies
? ? ? ? 11.3.3. Online Pharmacies
? ? 11.4. Market Attractiveness Analysis, by Distribution Channel
12. Global Ophthalmic Drugs Market Analysis and Forecast, by Region
? ? 12.1. Key Findings
? ? 12.2. Market Value Forecast, by Region
? ? ? ? 12.2.1. North America
? ? ? ? 12.2.2. Europe
? ? ? ? 12.2.3. Asia Pacific
? ? ? ? 12.2.4. Latin America
? ? ? ? 12.2.5. Middle East & Africa
? ? 12.3. Market Attractiveness Analysis, by Region
13. North America Ophthalmic Drugs Market Analysis and Forecast
? ? 13.1. Introduction
? ? ? ? 13.1.1. Key Findings
? ? 13.2. Market Value Forecast, by Therapeutic Class, 2017-2031
? ? ? ? 13.2.1. Anti-VEGF Agents
? ? ? ? 13.2.2. Anti-glaucoma Drugs

? ? ? ? ? 13.2.2.1. Alpha Agonist
? ? ? ? ? 13.2.2.2. Beta Blockers
? ? ? ? ? 13.2.2.3. Prostaglandin Analogs
? ? ? ? ? 13.2.2.4. Combined Medication
? ? ? ? ? 13.2.2.5. Others
? ? ? ? ? 13.2.3. Anti-inflammatory Drugs
? ? ? ? ? 13.2.3.1. Steroids
? ? ? ? ? 13.2.3.2. NSAIDs
? ? ? ? ? 13.2.4. Anti-infective Drugs
? ? ? ? ? 13.2.4.1. Anti-bacterial Drugs
? ? ? ? ? 13.2.4.2. Anti-fungal Drugs
? ? ? ? ? 13.2.4.3. Others
? ? ? ? ? 13.2.5. Anti-allergy Drugs
? ? ? ? ? 13.2.6. Others
?? 13.3. Market Value Forecast, by Indication, 2017-2031
?? ? ? ? 13.3.1. Dry Eye
?? ? ? ? 13.3.2. Glaucoma
?? ? ? ? 13.3.3. Infection/Inflammation
?? ? ? ? 13.3.4. Retinal Disorders
?? ? ? ? ? ? 13.3.4.1. Wet AMD
?? ? ? ? ? ? 13.3.4.2. Dry AMD
?? ? ? ? ? ? 13.3.4.3. Diabetic Retinopathy
?? ? ? ? ? ? 13.3.4.4. Others
?? ? ? ? ? ? 13.3.5. Allergy
?? ? ? ? ? ? 13.3.6. Uveitis
?? ? ? ? ? ? 13.3.7. Others
?? 13.4. Market Value Forecast, by Route of Administration, 2017-2031
?? ? ? ? ? ? 13.4.1. Topical
?? ? ? ? ? ? 13.4.2. Local Ocular (intravitreal)
?? ? ? ? ? ? 13.4.3. Others
?? 13.5. Market Value Forecast, by Product Type, 2017-2031
?? ? ? ? ? ? 13.5.1. Prescription
?? ? ? ? ? ? 13.5.2. OTC
?? 13.6. Market Value Forecast, by Dosage Form, 2017-2031
?? ? ? ? ? ? 13.6.1. Eye Drops
?? ? ? ? ? ? 13.6.2. Eye Solutions & Suspensions
?? ? ? ? ? ? 13.6.3. Capsules & Tablets
?? ? ? ? ? ? 13.6.4. Gels
?? ? ? ? ? ? 13.6.5. Ointments
?? ? ? ? ? ? 13.6.6. Others
?? 13.7. Market Value Forecast, by Distribution Channel, 2017-2031
?? ? ? ? ? ? 13.7.1. Hospital Pharmacies
?? ? ? ? ? ? 13.7.2. Retail Pharmacies
?? ? ? ? ? ? 13.7.3. Online Pharmacies
?? 13.8. Market Value Forecast, by Country, 2017-2031
?? ? ? ? ? ? 13.8.1. U.S.
?? ? ? ? ? ? 13.8.2. Canada

? ? 13.9. Market Attractiveness Analysis
?? ? ? 13.9.1. By Therapeutic Class
?? ? ? 13.9.2. By Indication
?? ? ? 13.9.3. By Route of Administration
?? ? ? 13.9.4. By Product Type
?? ? ? 13.9.5. By Dosage Form
?? ? ? 13.9.6. By Distribution Channel
?? ? ? 13.9.7. By Country

14. Europe Ophthalmic Drugs Market Analysis and Forecast
? ? 14.1. Introduction
?? ? ? 14.1.1. Key Findings
?? 14.2. Market Value Forecast, by Therapeutic Class, 2017-2031
?? ? ? 14.2.1. Anti-VEGF Agents
?? ? ? 14.2.2. Anti-glaucoma Drugs
???? ? ? 14.2.2.1. Alpha Agonist
???? ? ? 14.2.2.2. Beta Blockers
???? ? ? 14.2.2.3. Prostaglandin Analogs
???? ? ? 14.2.2.4. Combined Medication
???? ? ? 14.2.2.5. Others
?? ? ? 14.2.3. Anti-inflammatory Drugs
???? ? ? 14.2.3.1. Steroids
???? ? ? 14.2.3.2. NSAIDs
?? ? ? 14.2.4. Anti-infective Drugs
???? ? ? 14.2.4.1. Anti-bacterial Drugs
???? ? ? 14.2.4.2. Anti-fungal Drugs
???? ? ? 14.2.4.3. Others
?? ? ? 14.2.5. Anti-allergy Drugs
?? ? ? 14.2.6. Others

? ? 14.3. Market Value Forecast, by Indication, 2017-2031
?? ? ? 14.3.1. Dry Eye
?? ? ? 14.3.2. Glaucoma
?? ? ? 14.3.3. Infection/Inflammation
?? ? ? 14.3.4. Retinal Disorders
???? ? ? 14.3.4.1. Wet AMD
???? ? ? 14.3.4.2. Dry AMD
???? ? ? 14.3.4.3. Diabetic Retinopathy
???? ? ? 14.3.4.4. Others
?? ? ? 14.3.5. Allergy
?? ? ? 14.3.6. Uveitis
?? ? ? 14.3.7. Others

? ? 14.4. Market Value Forecast, by Route of Administration, 2017-2031
?? ? ? 14.4.1. Topical
?? ? ? 14.4.2. Local Ocular (intravitreal)
?? ? ? 14.4.3. Others

? ? 14.5. Market Value Forecast, by Product Type, 2017-2031
?? ? ? 14.5.1. Prescription
?? ? ? 14.5.2. OTC

? ? 14.6. Market Value Forecast, by Dosage Form, 2017-2031

? ? ? ? 14.6.1. Eye Drops

? ? ? ? 14.6.2. Eye Solutions & Suspensions

? ? ? ? 14.6.3. Capsules & Tablets

? ? ? ? 14.6.4. Gels

? ? ? ? 14.6.5. Ointments

? ? ? ? 14.6.6. Others

? ? 14.7. Market Value Forecast, by Distribution Channel, 2017-2031

? ? ? ? 14.7.1. Hospital Pharmacies

? ? ? ? 14.7.2. Retail Pharmacies

? ? ? ? 14.7.3. Online Pharmacies

? ? 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031

? ? ? ? 14.8.1. Germany

? ? ? ? 14.8.2. U.K.

? ? ? ? 14.8.3. France

? ? ? ? 14.8.4. Spain

? ? ? ? 14.8.5. Italy

? ? ? ? 14.8.6. Rest of Europe

? ? 14.9. Market Attractiveness Analysis

? ? ? ? 14.9.1. By Therapeutic Class

? ? ? ? 14.9.2. By Indication

? ? ? ? 14.9.3. By Route of Administration

? ? ? ? 14.9.4. By Product Type

? ? ? ? 14.9.5. By Dosage Form

? ? ? ? 14.9.6. By Distribution Channel

? ? ? ? 14.9.7. By Country/Sub-region

15. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast

? ? 15.1. Introduction

? ? ? ? 15.1.1. Key Findings

? ? 15.2. Market Value Forecast, by Therapeutic Class, 2017-2031

? ? ? ? 15.2.1. Anti-VEGF Agents

? ? ? ? 15.2.2. Anti-glaucoma Drugs

? ? ? ? ? 15.2.2.1. Alpha Agonist

? ? ? ? ? 15.2.2.2. Beta Blockers

? ? ? ? ? 15.2.2.3. Prostaglandin Analogs

? ? ? ? ? 15.2.2.4. Combined Medication

? ? ? ? ? 15.2.2.5. Others

? ? ? ? 15.2.3. Anti-inflammatory Drugs

? ? ? ? ? 15.2.3.1. Steroids

? ? ? ? ? 15.2.3.2. NSAIDs

? ? ? ? 15.2.4. Anti-infective Drugs

? ? ? ? ? 15.2.4.1. Anti-bacterial Drugs

? ? ? ? ? 15.2.4.2. Anti-fungal Drugs

? ? ? ? ? 15.2.4.3. Others

? ? ? ? 15.2.5. Anti-allergy Drugs

? ? ? ? 15.2.6. Others

? ? 15.3. Market Value Forecast, by Indication, 2017-2031

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

? ? ? ? 15.3.1. Dry Eye
? ? ? ? 15.3.2. Glaucoma
? ? ? ? 15.3.3. Infection/Inflammation
? ? ? ? 15.3.4. Retinal Disorders
? ? ? ? ? 15.3.4.1. Wet AMD
? ? ? ? ? 15.3.4.2. Dry AMD
? ? ? ? ? 15.3.4.3. Diabetic Retinopathy
? ? ? ? ? 15.3.4.4. Others
? ? ? ? 15.3.5. Allergy
? ? ? ? 15.3.6. Uveitis
? ? ? ? 15.3.7. Others

? ? 15.4. Market Value Forecast, by Route of Administration, 2017-2031
? ? ? ? 15.4.1. Topical
? ? ? ? 15.4.2. Local Ocular (intravitreal)
? ? ? ? 15.4.3. Others

? ? 15.5. Market Value Forecast, by Product Type, 2017-2031
? ? ? ? 15.5.1. Prescription
? ? ? ? 15.5.2. OTC

? ? 15.6. Market Value Forecast, by Dosage Form, 2017-2031
? ? ? ? 15.6.1. Eye Drops
? ? ? ? 15.6.2. Eye Solutions & Suspensions
? ? ? ? 15.6.3. Capsules & Tablets
? ? ? ? 15.6.4. Gels
? ? ? ? 15.6.5. Ointments
? ? ? ? 15.6.6. Others

? ? 15.7. Market Value Forecast, by Distribution Channel, 2017-2031
? ? ? ? 15.7.1. Hospital Pharmacies
? ? ? ? 15.7.2. Retail Pharmacies
? ? ? ? 15.7.3. Online Pharmacies

? ? 15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
? ? ? ? 15.8.1. China
? ? ? ? 15.8.2. Japan
? ? ? ? 15.8.3. India
? ? ? ? 15.8.4. Australia & New Zealand
? ? ? ? 15.8.5. Rest of Asia Pacific

? ? 15.9. Market Attractiveness Analysis
? ? ? ? 15.9.1. By Therapeutic Class
? ? ? ? 15.9.2. By Indication
? ? ? ? 15.9.3. By Route of Administration
? ? ? ? 15.9.4. By Product Type
? ? ? ? 15.9.5. By Dosage Form
? ? ? ? 15.9.6. By Distribution Channel
? ? ? ? 15.9.7. By Country/Sub-region

16. Latin America Ophthalmic Drugs Market Analysis and Forecast
? ? 16.1. Introduction
? ? ? ? 16.1.1. Key Findings
? ? 16.2. Market Value Forecast, by Therapeutic Class, 2017-2031

? ? ? ? 16.2.1. Anti-VEGF Agents
? ? ? ? 16.2.2. Anti-glaucoma Drugs
? ? ? ? ? 16.2.2.1. Alpha Agonist
? ? ? ? ? 16.2.2.2. Beta Blockers
? ? ? ? ? 16.2.2.3. Prostaglandin Analogs
? ? ? ? ? 16.2.2.4. Combined Medication
? ? ? ? ? 16.2.2.5. Others
? ? ? ? 16.2.3. Anti-inflammatory Drugs
? ? ? ? ? 16.2.3.1. Steroids
? ? ? ? ? 16.2.3.2. NSAIDs
? ? ? ? 16.2.4. Anti-infective Drugs
? ? ? ? ? 16.2.4.1. Anti-bacterial Drugs
? ? ? ? ? 16.2.4.2. Anti-fungal Drugs
? ? ? ? ? 16.2.4.3. Others
? ? ? ? 16.2.5. Anti-allergy Drugs
? ? ? ? 16.2.6. Others
? ? 16.3. Market Value Forecast, by Indication, 2017-2031
? ? ? ? 16.3.1. Dry Eye
? ? ? ? 16.3.2. Glaucoma
? ? ? ? 16.3.3. Infection/Inflammation
? ? ? ? 16.3.4. Retinal Disorders
? ? ? ? ? 16.3.4.1. Wet AMD
? ? ? ? ? 16.3.4.2. Dry AMD
? ? ? ? ? 16.3.4.3. Diabetic Retinopathy
? ? ? ? ? 16.3.4.4. Others
? ? ? ? 16.3.5. Allergy
? ? ? ? 16.3.6. Uveitis
? ? ? ? 16.3.7. Others
? ? 16.4. Market Value Forecast, by Route of Administration, 2017-2031
? ? ? ? 16.4.1. Topical
? ? ? ? 16.4.2. Local Ocular (intravitreal)
? ? ? ? 16.4.3. Others
? ? 16.5. Market Value Forecast, by Product Type, 2017-2031
? ? ? ? 16.5.1. Prescription
? ? ? ? 16.5.2. OTC
? ? 16.6. Market Value Forecast, by Dosage Form, 2017-2031
? ? ? ? 16.6.1. Eye Drops
? ? ? ? 16.6.2. Eye Solutions & Suspensions
? ? ? ? 16.6.3. Capsules & Tablets
? ? ? ? 16.6.4. Gels
? ? ? ? 16.6.5. Ointments
? ? ? ? 16.6.6. Others
? ? 16.7. Market Value Forecast, by Distribution Channel, 2017-2031
? ? ? ? 16.7.1. Hospital Pharmacies
? ? ? ? 16.7.2. Retail Pharmacies
? ? ? ? 16.7.3. Online Pharmacies
? ? 16.8. Market Value Forecast, by Country/Sub-region, 2017-2031

? ? ? ? 16.8.1. Brazil
? ? ? ? 16.8.2. Mexico
? ? ? ? 16.8.3. Rest of Latin America
? ? 16.9. Market Attractiveness Analysis
? ? ? ? 16.9.1. By Therapeutic Class
? ? ? ? 16.9.2. By Indication
? ? ? ? 16.9.3. By Route of Administration
? ? ? ? 16.9.4. By Product Type
? ? ? ? 16.9.5. By Dosage Form
? ? ? ? 16.9.6. By Distribution Channel
? ? ? ? 16.9.7. By Country/Sub-region
17. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast
? ? 17.1. Introduction
? ? ? ? 17.1.1. Key Findings
? ? 17.2. Market Value Forecast, by Therapeutic Class, 2017-2031
? ? ? ? 17.2.1. Anti-VEGF Agents
? ? ? ? 17.2.2. Anti-glaucoma Drugs
? ? ? ? ? 17.2.2.1. Alpha Agonist
? ? ? ? ? 17.2.2.2. Beta Blockers
? ? ? ? ? 17.2.2.3. Prostaglandin Analogs
? ? ? ? ? 17.2.2.4. Combined Medication
? ? ? ? ? 17.2.2.5. Others
? ? ? ? 17.2.3. Anti-inflammatory Drugs
? ? ? ? ? 17.2.3.1. Steroids
? ? ? ? ? 17.2.3.2. NSAIDs
? ? ? ? 17.2.4. Anti-infective Drugs
? ? ? ? ? 17.2.4.1. Anti-bacterial Drugs
? ? ? ? ? 17.2.4.2. Anti-fungal Drugs
? ? ? ? ? 17.2.4.3. Others
? ? ? ? 17.2.5. Anti-allergy Drugs
? ? ? ? 17.2.6. Others
? ? 17.3. Market Value Forecast, by Indication, 2017-2031
? ? ? ? 17.3.1. Dry Eye
? ? ? ? 17.3.2. Glaucoma
? ? ? ? 17.3.3. Infection/Inflammation
? ? ? ? 17.3.4. Retinal Disorders
? ? ? ? ? 17.3.4.1. Wet AMD
? ? ? ? ? 17.3.4.2. Dry AMD
? ? ? ? ? 17.3.4.3. Diabetic Retinopathy
? ? ? ? ? 17.3.4.4. Others
? ? ? ? 17.3.5. Allergy
? ? ? ? 17.3.6. Uveitis
? ? ? ? 17.3.7. Others
? ? 17.4. Market Value Forecast, by Route of Administration, 2017-2031
? ? ? ? 17.4.1. Topical
? ? ? ? 17.4.2. Local Ocular (intravitreal)
? ? ? ? 17.4.3. Others

? ? 17.5. Market Value Forecast, by Product Type, 2017-2031
?? ? ? 17.5.1. Prescription
?? ? ? 17.5.2. OTC
? ? 17.6. Market Value Forecast, by Dosage Form, 2017-2031
?? ? ? 17.6.1. Eye Drops
?? ? ? 17.6.2. Eye Solutions & Suspensions
?? ? ? 17.6.3. Capsules & Tablets
?? ? ? 17.6.4. Gels
?? ? ? 17.6.5. Ointments
?? ? ? 17.6.6. Others
? ? 17.7. Market Value Forecast, by Distribution Channel, 2017-2031
?? ? ? 17.7.1. Hospital Pharmacies
?? ? ? 17.7.2. Retail Pharmacies
?? ? ? 17.7.3. Online Pharmacies
? ? 17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
?? ? ? 17.8.1. GCC Countries
?? ? ? 17.8.2. South Africa
?? ? ? 17.8.3. Rest of Middle East & Africa
? ? 17.9. Market Attractiveness Analysis
?? ? ? 17.9.1. By Therapeutic Class
?? ? ? 17.9.2. By Indication
?? ? ? 17.9.3. By Route of Administration
?? ? ? 17.9.4. By Product Type
?? ? ? 17.9.5. By Dosage Form
?? ? ? 17.9.6. By Distribution Channel
?? ? ? 17.9.7. By Country/Sub-region

18. Competition Landscape

? ? 18.1. Market Player - Competition Matrix (by tier and size of companies)
? ? 18.2. Market Share Analysis, by Company, 2022
? ? 18.3. Company Profiles

? ? ? ? 18.3.1. AbbVie, Inc.

? ? ? ? ? 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
? ? ? ? ? 18.3.1.2. Product Portfolio
? ? ? ? ? 18.3.1.3. Financial Overview
? ? ? ? ? 18.3.1.4. SWOT Analysis
? ? ? ? ? 18.3.1.5. Strategic Overview

? ? ? ? 18.3.2. Alcon Vision LLC

? ? ? ? ? 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
? ? ? ? ? 18.3.2.2. Product Portfolio
? ? ? ? ? 18.3.2.3. Financial Overview
? ? ? ? ? 18.3.2.4. SWOT Analysis
? ? ? ? ? 18.3.2.5. Strategic Overview

? ? ? ? 18.3.3. Bausch Health Companies, Inc.

? ? ? ? ? 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
? ? ? ? ? 18.3.3.2. Product Portfolio
? ? ? ? ? 18.3.3.3. Financial Overview
? ? ? ? ? 18.3.3.4. SWOT Analysis

????? 18.3.3.5. Strategic Overview
????? 18.3.4. Bayer AG
????? 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
????? 18.3.4.2. Product Portfolio
????? 18.3.4.3. Financial Overview
????? 18.3.4.4. SWOT Analysis
????? 18.3.4.5. Strategic Overview
????? 18.3.5. Coherus BioSciences
????? 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
????? 18.3.5.2. Product Portfolio
????? 18.3.5.3. Financial Overview
????? 18.3.5.4. SWOT Analysis
????? 18.3.5.5. Strategic Overview
????? 18.3.6. F. Hoffmann-La Roche Ltd.
????? 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
????? 18.3.6.2. Product Portfolio
????? 18.3.6.3. Financial Overview
????? 18.3.6.4. SWOT Analysis
????? 18.3.6.5. Strategic Overview
????? 18.3.7. Novartis Pharmaceuticals Corporation
????? 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
????? 18.3.7.2. Product Portfolio
????? 18.3.7.3. Financial Overview
????? 18.3.7.4. SWOT Analysis
????? 18.3.7.5. Strategic Overview
????? 18.3.8. Pfizer, Inc.
????? 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
????? 18.3.8.2. Product Portfolio
????? 18.3.8.3. Financial Overview
????? 18.3.8.4. SWOT Analysis
????? 18.3.8.5. Strategic Overview
????? 18.3.9. Regeneron Pharmaceuticals, Inc.
????? 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
????? 18.3.9.2. Product Portfolio
????? 18.3.9.3. Financial Overview
????? 18.3.9.4. SWOT Analysis
????? 18.3.9.5. Strategic Overview
????? 18.3.10. Santen, Inc.
????? 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
????? 18.3.10.2. Product Portfolio
????? 18.3.10.3. Financial Overview
????? 18.3.10.4. SWOT Analysis
????? 18.3.10.5. Strategic Overview
????? 18.3.11. Sun Pharmaceutical Industries Ltd.
????? 18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
????? 18.3.11.2. Product Portfolio
????? 18.3.11.3. Financial Overview

????? 18.3.11.4. SWOT Analysis

????? 18.3.11.5. Strategic Overview

??? 18.3.12. Teva Pharmaceutical Industries Ltd.

????? 18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

????? 18.3.12.2. Product Portfolio

????? 18.3.12.3. Financial Overview

????? 18.3.12.4. SWOT Analysis

????? 18.3.12.5. Strategic Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Ophthalmic Drugs Market (Therapeutic Class: Anti-VEGF Agents, Anti-glaucoma Drugs, Anti-inflammatory Drugs, Anti-infective Drugs, Anti-allergy Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Report | 2023-05-11 | 292 pages | Transparency Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5795.00
	Multi User License	\$8795.00
	Global Site License	\$11795.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784


tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-12

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com